Module 7: Special Populations
Lipid management considerations for special populations including women, older adults, and ethnic groups.
Special Population Guidance
Select a population for guideline-specific statin and lipid management recommendations
CKD Assessment
Enter eGFR to see stage-specific guidance
Statin Guidance
Class I / Level AFollow standard statin recommendations. CKD is a recognized risk-enhancing factor.
Recommendation
CKD Stage 1-2 (eGFR ≥60): Manage lipids per standard primary or secondary prevention pathways. CKD at this stage is a risk-enhancing factor that favors statin initiation.
Source: Section 4.2.8.8, Recommendation - CKD Stage 1-2 (standard pathway)
Understanding the Evidence Rating
Drug Interactions & Contraindications
Drug Interactions
Avoid simvastatin >20 mg with cyclosporine
Preferred statins in CKD: atorvastatin, rosuvastatin, pitavastatin (renal-safe profiles)
Clinical Pearls
- CKD is a recognized risk-enhancing factor at any stage.
- Statins do not adversely affect kidney function and may slow CKD progression.
- PCSK9 inhibitors can be used without dose adjustment across all CKD stages.
- Avoid simvastatin >20 mg with cyclosporine in CKD patients who are also transplant recipients.
This tool is intended for use by healthcare professionals and does not replace clinical judgment. Always refer to the full 2026 ACC/AHA Guideline on the Management of Dyslipidemia for complete recommendations.